We are live on
!
Find out more
Royalty Pharma
RPRX
RPRX
213 hedge funds and large institutions have $10.8B invested in Royalty Pharma in 2021 Q1 according to their latest regulatory filings, with 49 funds opening new positions, 85 increasing their positions, 56 reducing their positions, and 34 closing their positions.
New
Increased
Maintained
Reduced
Closed
52% more repeat investments, than reductions
Existing positions increased: 85 | Existing positions reduced: 56
44% more first-time investments, than exits
New positions opened: 49 | Existing positions closed: 34
10% more funds holding in top 10
Funds holding in top 10: 10 → 11 (+1)
8% more funds holding
Funds holding: 198 → 213 (+15)
4.44% more ownership
Funds ownership: 59.3% → 63.74% (+4.4%)
2% more call options, than puts
Call options by funds: $46.5M | Put options by funds: $45.7M
5% less capital invested
Capital invested by funds: $11.4B → $10.8B (-$608M)
Holders
213
Holders Change
+15
Holders Change %
+7.58%
% of All Funds
3.74%
Holding in Top 10
11
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+10%
% of All Funds
0.19%
New
49
Increased
85
Reduced
56
Closed
34
Calls
$46.5M
Puts
$45.7M
Net Calls
+$871K
Net Calls Change
+$22.2M
Top Buyers
| 1 |
Morgan Stanley
New York
|
+$1.15B |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$980M |
| 3 |
BlackRock
New York
|
+$219M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$143M |
| 5 |
State Street
Boston,
Massachusetts
|
+$110M |
